355 related articles for article (PubMed ID: 23074173)
1. The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.
Lui GY; Obeidy P; Ford SJ; Tselepis C; Sharp DM; Jansson PJ; Kalinowski DS; Kovacevic Z; Lovejoy DB; Richardson DR
Mol Pharmacol; 2013 Jan; 83(1):179-90. PubMed ID: 23074173
[TBL] [Abstract][Full Text] [Related]
2. The oral iron chelator deferasirox induces apoptosis in myeloid leukemia cells by targeting caspase.
Kim JL; Kang HN; Kang MH; Yoo YA; Kim JS; Choi CW
Acta Haematol; 2011; 126(4):241-5. PubMed ID: 21951998
[No Abstract] [Full Text] [Related]
3. Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status.
Lee DH; Jang PS; Chung NG; Cho B; Jeong DC; Kim HK
Exp Hematol; 2013 Jun; 41(6):539-46. PubMed ID: 23415674
[TBL] [Abstract][Full Text] [Related]
4. Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo.
Ford SJ; Obeidy P; Lovejoy DB; Bedford M; Nichols L; Chadwick C; Tucker O; Lui GY; Kalinowski DS; Jansson PJ; Iqbal TH; Alderson D; Richardson DR; Tselepis C
Br J Pharmacol; 2013 Mar; 168(6):1316-28. PubMed ID: 23126308
[TBL] [Abstract][Full Text] [Related]
5. The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1.
Ohyashiki JH; Kobayashi C; Hamamura R; Okabe S; Tauchi T; Ohyashiki K
Cancer Sci; 2009 May; 100(5):970-7. PubMed ID: 19298223
[TBL] [Abstract][Full Text] [Related]
6. Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo.
Harima H; Kaino S; Takami T; Shinoda S; Matsumoto T; Fujisawa K; Yamamoto N; Yamasaki T; Sakaida I
BMC Cancer; 2016 Aug; 16(1):702. PubMed ID: 27582255
[TBL] [Abstract][Full Text] [Related]
7. The potential of deferasirox as a novel therapeutic modality in gastric cancer.
Choi JH; Kim JS; Won YW; Uhm J; Park BB; Lee YY
World J Surg Oncol; 2016 Mar; 14():77. PubMed ID: 26965928
[TBL] [Abstract][Full Text] [Related]
8. Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic cancer.
Kovacevic Z; Chikhani S; Lovejoy DB; Richardson DR
Mol Pharmacol; 2011 Oct; 80(4):598-609. PubMed ID: 21719465
[TBL] [Abstract][Full Text] [Related]
9. The Iron Chelator, Dp44mT, Effectively Inhibits Human Oral Squamous Cell Carcinoma Cell Growth in Vitro and in Vivo.
Lee JC; Chiang KC; Feng TH; Chen YJ; Chuang ST; Tsui KH; Chung LC; Juang HH
Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27589737
[TBL] [Abstract][Full Text] [Related]
10. Potent iron chelators increase the mRNA levels of the universal cyclin-dependent kinase inhibitor p21(CIP1/WAF1), but paradoxically inhibit its translation: a potential mechanism of cell cycle dysregulation.
Le NT; Richardson DR
Carcinogenesis; 2003 Jun; 24(6):1045-58. PubMed ID: 12807743
[TBL] [Abstract][Full Text] [Related]
11. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
Chaston TB; Lovejoy DB; Watts RN; Richardson DR
Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of the antitumoral activity of deferasirox, an iron chelation agent, on mantle cell lymphoma.
Vazana-Barad L; Granot G; Mor-Tzuntz R; Levi I; Dreyling M; Nathan I; Shpilberg O
Leuk Lymphoma; 2013 Apr; 54(4):851-9. PubMed ID: 23020673
[TBL] [Abstract][Full Text] [Related]
13. Iron chelation in the treatment of cancer: a new role for deferasirox?
Bedford MR; Ford SJ; Horniblow RD; Iqbal TH; Tselepis C
J Clin Pharmacol; 2013 Sep; 53(9):885-91. PubMed ID: 23740857
[TBL] [Abstract][Full Text] [Related]
14. Effects of deferasirox and deferiprone on cellular iron load in the human hepatoma cell line HepaRG.
Gaboriau F; Leray AM; Ropert M; Gouffier L; Cannie I; Troadec MB; Loréal O; Brissot P; Lescoat G
Biometals; 2010 Apr; 23(2):231-45. PubMed ID: 19997770
[TBL] [Abstract][Full Text] [Related]
15. Deferasirox--an oral agent for chronic iron overload.
Vanorden HE; Hagemann TM
Ann Pharmacother; 2006 Jun; 40(6):1110-7. PubMed ID: 16735647
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, characterization and in vitro anticancer evaluations of two novel derivatives of deferasirox iron chelator.
Salehi S; Saljooghi ASh; Shiri A
Eur J Pharmacol; 2016 Jun; 781():209-17. PubMed ID: 27090924
[TBL] [Abstract][Full Text] [Related]
17. Deferasirox reduces iron overload in a murine model of juvenile hemochromatosis.
Nick H; Allegrini PR; Fozard L; Junker U; Rojkjaer L; Salie R; Niederkofler V; O'Reilly T
Exp Biol Med (Maywood); 2009 May; 234(5):492-503. PubMed ID: 19234060
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1).
Patel V; Lahusen T; Leethanakul C; Igishi T; Kremer M; Quintanilla-Martinez L; Ensley JF; Sausville EA; Gutkind JS; Senderowicz AM
Clin Cancer Res; 2002 Nov; 8(11):3549-60. PubMed ID: 12429646
[TBL] [Abstract][Full Text] [Related]
19. Deferasirox: the new oral iron chelator.
Dubey AP; Sudha S; Parakh A
Indian Pediatr; 2007 Aug; 44(8):603-7. PubMed ID: 17827637
[TBL] [Abstract][Full Text] [Related]
20. Rhabdoid tumor growth is inhibited by flavopiridol.
Smith ME; Cimica V; Chinni S; Challagulla K; Mani S; Kalpana GV
Clin Cancer Res; 2008 Jan; 14(2):523-32. PubMed ID: 18223228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]